ISIS 14803-CS2, treatment with ISIS 14803, administered IV [intravenously] in patients with chronic hepatitis C virus infections
Phase of Trial: Phase II
Latest Information Update: 25 Jan 2016
At a glance
- Drugs ISIS 14803 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 15 Oct 2007 Status changed from in progress to completed.
- 22 Oct 2005 New trial record.